Table 1 Characteristics of the patients at baseline
Characteristic | DL1 (N = 1) | DL2 (N = 3) | DL3 (N = 4) | DL4 (N = 1) | |||||
|---|---|---|---|---|---|---|---|---|---|
P1 | P2 | P3 | P4 | P5 | P6 | P7 | P8 | P9 | |
Sex | M | F | F | F | F | F | M | F | F |
Age | 25 | 60 | 32 | 34 | 28 | 57 | 37 | 36 | 40 |
FAB | M4 | M4 | M5 | M4 | M5 | M4 | M5 | M5 | M5 |
Gene mutation | No | TP53 | NRAS,IDH1 | NPM1+,DNMT3A+ | KMT2A::AF10, FLT3-ITD | KMT2A-PTD, FLT3-ITD | KMT2A::AF10,FLT3-ITD | KMT2A::AF10 | NUP98::HOXA9 |
Karyotype | −Y | Complex | −7 | Normal | t(10;11) (p12;q23) | +8 | t(10;11) (p12;q23) | t(10;11) (p12;q23) | t(7;11) (p15;p15) |
ELN 2022 | Int | Adv | Adv | Fav | Int | Int | Adv | Adv | Int |
MDS/MPN | No | No | No | No | No | CMML-AML | No | No | No |
Extramedullary invasion | No | No | No | No | No | No | No | No | No |
Previous lines of therapy | 2 | 3 | 3 | 4 | 2 | 1 | 3 | 3 | 5 |
Previous Allo-HSCT | Yes | Yes | No | Yes | No | Yes | Yes | Yes | Yes |
BM blast(%)# At Enrollment | 55.00 | 59.5 | 17.50 | 8.00 | 81.50 | 8.00 | 10.00 | 6.00 | 10.00 |
LILRB4(%)* | 85.52 | 56.26 | 78.72 | 44.00 | 94.04 | 49.00 | 94.39 | 79.50 | 90.00 |
Origin of T cells | Autologous | Autologous | Autologous | Allogeneic | Autologous | Allogeneic | Allogeneic | Allogeneic | Allogeneic |
